PRPH2-targeted antisense oligonucleotide

antisense oligonucleotide targeting PRPH2 · n-Lorem Foundation

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for PRPH2-targeted antisense oligonucleotide, covering 2025-09-16 to 2025-09-16. Get the full timeline:

Most recent: Clinical Trial Update: Personalized Antisense Oligonucleotide Therapy for a Single Participant With PRPH2 Mutation Associated With Retinal Dystrophy [Phase 1, Phase 2]

See pricing